<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Palliat Med</journal-id><journal-id journal-id-type="iso-abbrev">Palliat Med</journal-id><journal-id journal-id-type="publisher-id">PMJ</journal-id><journal-id journal-id-type="hwp">sppmj</journal-id><journal-title-group><journal-title>Palliative Medicine</journal-title></journal-title-group><issn pub-type="ppub">0269-2163</issn><issn pub-type="epub">1477-030X</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29688127</article-id><article-id pub-id-type="pmc">5967038</article-id><article-id pub-id-type="doi">10.1177/0269216318763225</article-id><article-id pub-id-type="publisher-id">10.1177_0269216318763225</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6204-9158</contrib-id><name><surname>Johnson</surname><given-names>Miriam J</given-names></name><xref ref-type="aff" rid="aff1-0269216318763225">1</xref><xref ref-type="corresp" rid="corresp1-0269216318763225"/></contrib><contrib contrib-type="author"><name><surname>McSkimming</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="aff2-0269216318763225">2</xref></contrib><contrib contrib-type="author"><name><surname>McConnachie</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff2-0269216318763225">2</xref></contrib><contrib contrib-type="author"><name><surname>Geue</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff3-0269216318763225">3</xref></contrib><contrib contrib-type="author"><name><surname>Millerick</surname><given-names>Yvonne</given-names></name><xref ref-type="aff" rid="aff4-0269216318763225">4</xref></contrib><contrib contrib-type="author"><name><surname>Briggs</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff5-0269216318763225">5</xref></contrib><contrib contrib-type="author"><name><surname>Hogg</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="aff6-0269216318763225">6</xref></contrib></contrib-group><aff id="aff1-0269216318763225"><label>1</label>Wolfson Palliative Care Research Centre, Hull York Medical School and University of Hull, Hull, UK</aff><aff id="aff2-0269216318763225"><label>2</label>Robertson Centre for Biostatistics, Institute of Health &#x00026; Wellbeing, University of Glasgow, Glasgow, UK</aff><aff id="aff3-0269216318763225"><label>3</label>Health Economics and Health Technology Assessment, Institute of Health &#x00026; Wellbeing, University of Glasgow, Glasgow, UK</aff><aff id="aff4-0269216318763225"><label>4</label>Glasgow Caledonian University, British Heart Foundation, NHS Greater Glasgow and Clyde, Glasgow, UK</aff><aff id="aff5-0269216318763225"><label>5</label>William R Lindsay Chair of Health Economics (Health Economics and Health Technology Assessment), Institute of Health &#x00026; Wellbeing, University of Glasgow, Glasgow, UK</aff><aff id="aff6-0269216318763225"><label>6</label>Glasgow University, Glasgow, UK</aff><author-notes><corresp id="corresp1-0269216318763225">Miriam J Johnson, Wolfson Palliative Care Research Centre, Hull York Medical School and University of Hull, Allam Medical Building, Hull HU6 7RX, UK. Email: <email>Miriam.johnson@hyms.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><volume>32</volume><issue>6</issue><fpage>1133</fpage><lpage>1141</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="open-access" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-0269216318763225"><title>Background:</title><p>The effectiveness of cardiology-led palliative care is unknown; we have insufficient information to conduct a full trial.</p></sec><sec id="section2-0269216318763225"><title>Aim:</title><p>To assess the feasibility (recruitment/retention, data quality, variability/sample size estimation, safety) of a clinical trial of palliative cardiology effectiveness.</p></sec><sec id="section3-0269216318763225"><title>Design:</title><p>Non-randomised feasibility.</p></sec><sec id="section4-0269216318763225"><title>Setting/participants:</title><p>Unmatched symptomatic heart failure patients on optimal cardiac treatment from (1) cardiology-led palliative service (caring together group) and (2) heart failure liaison service (usual care group).</p></sec><sec id="section5-0269216318763225"><title>Outcomes/safety:</title><p>Symptoms (Edmonton Symptom Assessment Scale), Kansas City Cardiomyopathy Questionnaire, performance, understanding of disease, anticipatory care planning, cost-effectiveness, survival and carer burden.</p></sec><sec id="section6-0269216318763225" sec-type="results"><title>Results:</title><p>A total of 77 participants (caring together group&#x02009;=&#x02009;43; usual care group&#x02009;=&#x02009;34) were enrolled (53% men; mean age 77&#x02009;years (33&#x02013;100)). The caring together group scored worse in Edmonton Symptom Assessment Scale (43.5 vs 35.2) and Kansas City Cardiomyopathy Questionnaire (35.4 vs 39.9). The caring together group had a lower consent/screen ratio (1:1.7 vs 1: 2.8) and few died before approach (0.08% vs 16%) or declined invitation (17% vs 37%).</p></sec><sec id="section7-0269216318763225"><title>Data quality:</title><p>At 4&#x02009;months, 74% in the caring together group and 71% in the usual care group provided data. Most attrition was due to death or deterioration. Data quality in self-report measures was otherwise good.</p></sec><sec id="section8-0269216318763225"><title>Safety:</title><p>There was no difference in survival. Symptoms and quality of life improved in both groups. A future trial requires 141 (202 allowing 30% attrition) to detect a minimal clinical difference (1 point) in Edmonton Symptom Assessment Scale score for breathlessness (80% power). More participants (176; 252 allowing 30% attrition) are needed to detect a 10.5 change in Kansas City Cardiomyopathy Questionnaire score (80% power; minimum clinical difference&#x02009;=&#x02009;5).</p></sec><sec id="section9-0269216318763225" sec-type="conclusions"><title>Conclusion:</title><p>A trial to test the clinical effectiveness (improvement in breathlessness) of cardiology-led palliative care is feasible.</p></sec></abstract><kwd-group><kwd>Palliative care</kwd><kwd>effectiveness</kwd><kwd>heart failure</kwd><kwd>feasibility studies</kwd></kwd-group><funding-group><award-group id="award1-0269216318763225"><funding-source id="funding1-0269216318763225"><institution-wrap><institution>British Heart Foundation</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000274</institution-id></institution-wrap></funding-source><award-id rid="funding1-0269216318763225">commissioned</award-id></award-group><award-group id="award2-0269216318763225"><funding-source id="funding2-0269216318763225"><institution-wrap><institution>Marie Curie Cancer Care</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000654</institution-id></institution-wrap></funding-source><award-id rid="funding2-0269216318763225">commissioned</award-id></award-group></funding-group></article-meta></front><body><boxed-text id="boxed-text1-0269216318763225" position="float" orientation="portrait"><p>
<bold>What is already known about the topic?</bold>
</p><list list-type="bullet" id="list1-0269216318763225"><list-item><p>Compared with people with cancer, those with advanced heart failure have equivalent palliative care needs with poorer access to specialist palliative care.</p></list-item><list-item><p>A palliative care approach led by cardiology teams and access to specialist palliative care according to need rather than prognosis is recommended but poorly implemented.</p></list-item><list-item><p>The evidence base for palliative care in heart failure is less robust than that for cancer and there are no published prospectively collected data for cardiology-led palliative care services.</p></list-item></list><p>
<bold>What this paper adds?</bold>
</p><list list-type="bullet" id="list2-0269216318763225"><list-item><p>Novel prospectively collected data for cardiology-led palliative care services which show that a future trial of cardiology-led palliative care is feasible in terms of recruitment to a clinical study (note: willingness to randomisation was not tested), data quality and sample size.</p></list-item><list-item><p>Data generating a hypothesis that cardiology-led palliative care may safely improve advance care planning and patients&#x02019; understanding of their condition, enable care at home and reduce costs.</p></list-item></list><p>
<bold>Implications for practice, theory or policy</bold>
</p><list list-type="bullet" id="list3-0269216318763225"><list-item><p>Findings should be tested in an adequately powered randomised controlled trial.</p></list-item><list-item><p>Future studies should identify and randomise patients with more severe or complex palliative care needs to ensure optimal use of finite specialist palliative care resources.</p></list-item></list></boxed-text><sec sec-type="intro" id="section10-0269216318763225"><title>Introduction</title><p>Compared with people with cancer, those with advanced heart failure have equivalent palliative care needs with poorer access to specialist palliative care.<sup><xref rid="bibr1-0269216318763225" ref-type="bibr">1</xref><xref rid="bibr2-0269216318763225" ref-type="bibr"/><xref rid="bibr3-0269216318763225" ref-type="bibr"/><xref rid="bibr4-0269216318763225" ref-type="bibr"/><xref rid="bibr5-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr6-0269216318763225" ref-type="bibr">6</xref></sup> Palliative care is recommended,<sup><xref rid="bibr7-0269216318763225" ref-type="bibr">7</xref><xref rid="bibr8-0269216318763225" ref-type="bibr"/><xref rid="bibr9-0269216318763225" ref-type="bibr"/><xref rid="bibr10-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr10-0269216318763225" ref-type="bibr">10</xref></sup> but poorly implemented.<sup><xref rid="bibr11-0269216318763225" ref-type="bibr">11</xref><xref rid="bibr12-0269216318763225" ref-type="bibr"/><xref rid="bibr13-0269216318763225" ref-type="bibr"/><xref rid="bibr14-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr15-0269216318763225" ref-type="bibr">15</xref></sup></p><p>Phase III trials of specialist palliative care for people with heart failure<sup><xref rid="bibr16-0269216318763225" ref-type="bibr">16</xref><xref rid="bibr17-0269216318763225" ref-type="bibr"/><xref rid="bibr18-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr19-0269216318763225" ref-type="bibr">19</xref></sup> report cost-effective<sup><xref rid="bibr20-0269216318763225" ref-type="bibr">20</xref>,<xref rid="bibr21-0269216318763225" ref-type="bibr">21</xref></sup> benefit with specialist palliative care without compromising survival. However, most palliative concerns in people with heart failure can be managed by the usual care team using a patient-centred approach with access to specialist palliative care for complex issues only.<sup><xref rid="bibr22-0269216318763225" ref-type="bibr">22</xref>,<xref rid="bibr23-0269216318763225" ref-type="bibr">23</xref></sup> Previous integrated service descriptions do not include patient-reported outcomes,<sup><xref rid="bibr24-0269216318763225" ref-type="bibr">24</xref><xref rid="bibr25-0269216318763225" ref-type="bibr"/><xref rid="bibr26-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr27-0269216318763225" ref-type="bibr">27</xref></sup> and the effectiveness of cardiology-led palliative care is untested.</p><p>A partnership between two charities (Marie Curie and British Heart Foundation) and a Scottish NHS health board developed cardiology-led models of heart failure palliative care (&#x02018;The Caring Together (CT) Programme&#x02019;<sup><xref rid="bibr28-0269216318763225" ref-type="bibr">28</xref></sup>).</p><p>The study objectives were to assess the feasibility of a future randomised controlled trial (RCT) in terms of (1) recruitment/retention, (2) data quality, (3) variability/sample size estimation and (4) safety.</p></sec><sec sec-type="methods" id="section11-0269216318763225"><title>Methods</title><p>Expanded methods are available online.</p><sec id="section12-0269216318763225"><title>Study design</title><p>This prospective feasibility cohort single-site study (data collection at baseline, 2 and 4&#x02009;months) used two heart failure outpatient groups. The participants continued 2&#x02009;monthly measures until the last recruit completed 4&#x02009;months&#x02019; follow-up.</p><p>Ethical (NRES Committee London &#x02013; Camberwell St Giles. REF 14/LO/1813; 07.10.2014) and institutional approvals were obtained prior to recruitment. The participants gave written informed consent.</p></sec><sec id="section13-0269216318763225"><title>Participants</title><p>Participants were adults with symptomatic heart failure (reduced or normal left ventricular ejection fraction; HFrEF, HFnEF) and family carers. Participants with at least one CT clinic attendance formed the caring together group (CTG). A convenience unmatched usual care group (UCG) was formed from heart failure liaison nurse service patients fulfilling CT criteria but who had not been referred. The risk of contamination was deemed to be minimal.<sup><xref rid="bibr29-0269216318763225" ref-type="bibr">29</xref></sup></p></sec><sec id="section14-0269216318763225"><title>Caring together intervention</title><p><xref ref-type="table" rid="table6-0269216318763225">Box 1</xref> shows the referral criteria and components. Collaborative primary and secondary care is led by a consultant cardiologist and a heart failure palliative care nurse consultant, through a palliative cardiology multi-disciplinary team (MDT).</p><table-wrap id="table6-0269216318763225" orientation="portrait" position="float"><label>Box 1.</label><caption><p>Caring together components (adapted, Caring Together Manualisation Report, 2014).<sup><xref rid="bibr28-0269216318763225" ref-type="bibr">28</xref></sup></p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table6"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/></colgroup><tbody><tr><td rowspan="1" colspan="1">I. Patient identification and referral<break/>&#x02003;&#x02022;&#x02003;Diagnosis of heart failure<sup><xref ref-type="table-fn" rid="table-fn12-0269216318763225">a</xref></sup> (NYHA III or IV).<break/>&#x02003;&#x02022;&#x02003;Distressing or debilitating symptoms despite optimal medical therapy.<break/>&#x02003;Supportive or palliative care needs (physical, social, emotional, spiritual or psychological).<break/>II. Holistic assessment<break/>&#x02003;&#x02022;&#x02003;Cardiology review.<break/>&#x02003;&#x02022;&#x02003;Holistic assessment: review with patient and carer needs, identification of individually tailored solutions.<break/>III. Care management and coordination<break/>&#x02003;&#x02022;&#x02003;Care manager assigned (usually heart failure nurse specialist) as the main contact for care management, information, advice and support.<break/>IV. Training and education<break/>&#x02003;&#x02022;&#x02003;Training provided to stakeholders delivering services within the programme.<break/>&#x02003;&#x02022;&#x02003;Shared learning between specialties (palliative care/cardiology and service delivery settings, community/acute care).<break/>V. Multi-disciplinary work and joint working<break/>&#x02003;&#x02022;&#x02003;Joint working and care coordination across teams (community, out-of-hours care, acute care): problems identified during the holistic assessment may trigger referral to other agencies or other MDT members, including primary care.<break/>&#x02003;&#x02022;&#x02003;Care manager coordinates care with the MDT and actions additional referrals if required.<break/>&#x02003;&#x02022;&#x02003;Individually tailored medical anticipatory care plan (MACP), including tailored anticipated medical interventions, such as cardiopulmonary resuscitation status decisions, device management and place of care/death shared with all members of the healthcare team including out-of-hours teams and specialist palliative care as needed.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn12-0269216318763225"><label>a</label><p>Patients with reduced or normal left ventricular function are eligible.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section15-0269216318763225"><title>Usual care</title><p>The liaison nurse service and other consultant cardiologists&#x02019; clinics provide education, self-care promotion, medical therapy up-titration and patient/family support (HFrEF only).</p></sec><sec id="section16-0269216318763225"><title>Study measures</title><list list-type="order" id="list4-0269216318763225"><list-item><p>Recruitment: screen-to-consent ratio, reasons for non-consent, recruitment rate, retention.</p></list-item><list-item><p>Data quality of protocol measures.<list list-type="simple" id="list5-0269216318763225"><list-item><p>(a)&#x02003;Demographic and clinical measures at baseline: New York Heart Association (NYHA) status;<sup><xref rid="bibr30-0269216318763225" ref-type="bibr">30</xref></sup> Australian-modified Karnofsky Performance Status (AKPS);<sup><xref rid="bibr31-0269216318763225" ref-type="bibr">31</xref></sup> Charlson et al.&#x02019;s<sup><xref rid="bibr32-0269216318763225" ref-type="bibr">32</xref></sup> comorbidity index; medication-optimised cardiac treatment; pulse, heart rate, presence/absence of oedema and jugular venous pressure; urea and electrolytes; and echocardiogram (HFrEF and HFnEF; for HFrEF, &#x02018;mild, moderate, severe&#x02019;, ejection fraction).</p></list-item><list-item><p>(b)&#x02003;Patient measures at baseline and follow-up: AKPS, Edmonton Symptom Assessment Scale &#x02013; revised (ESAS-r),<sup><xref rid="bibr33-0269216318763225" ref-type="bibr">33</xref></sup> Kansas City Cardiomyopathy Questionnaire (KCCQ-12),<sup><xref rid="bibr34-0269216318763225" ref-type="bibr">34</xref><xref rid="bibr35-0269216318763225" ref-type="bibr"/>&#x02013;<xref rid="bibr36-0269216318763225" ref-type="bibr">36</xref></sup> EuroQol EQ-5D-5L,<sup><xref rid="bibr37-0269216318763225" ref-type="bibr">37</xref></sup> Hospital Anxiety and Depression Scale (HADS),<sup><xref rid="bibr38-0269216318763225" ref-type="bibr">38</xref></sup> patient understanding (Likert), health service utilisation and costs (including medication) and Zarit 6 caregiver burden (carers).<sup><xref rid="bibr39-0269216318763225" ref-type="bibr">39</xref></sup></p></list-item><list-item><p>(c)&#x02003;Clinical measures at baseline and follow-up: survival, clinical documentation of anticipatory care planning (ACP).</p></list-item></list></p></list-item><list-item><p>Candidate primary outcome data variability for power estimation.</p></list-item><list-item><p>Safety: survival (6&#x02009;months) and outcomes (4&#x02009;months).</p></list-item></list><p>Data were not collected on willingness to be randomised.</p></sec><sec id="section17-0269216318763225"><title>Statistical analysis</title><p>Data are presented using descriptive statistics. Sample size estimations were conducted based on variability data around candidate primary outcomes.</p><p>Safety assessment: (1) Cox proportional hazards models were used for between-group survival differences and (2) Group 4&#x02009;month outcomes comparison by study entry group used two-sample <italic>t</italic> tests (continuous) and Fisher&#x02019;s exact tests (categorical), unless otherwise stated. No adjustments were made for multiple comparisons. Missing data were not imputed. A &#x02018;per-protocol&#x02019; (PP) repeated-measures model analysis excluded UCG participants referred to CT. Two random-effects repeated-measures regression models with (1) the KCCQ-12 and (2) the EQ-5D-5L, as the dependent outcomes adjusted for age, sex and baseline ESAS-r scores, were used. The estimated between-group differences were reported with 95% confidence intervals (CIs) and <italic>p</italic> values. PP analysis was completed for the initial repeated-measures model (data available).</p><p>Incremental costs and outcomes associated with CTG were determined. Resource use items included health service utilisation and medication. Analyses were conducted using SAS for Windows version 9.3. Formal power calculation was inappropriate.</p></sec></sec><sec sec-type="results" id="section18-0269216318763225"><title>Results</title><p>A total of 77 participants (43 CTG and 34 UCG) were recruited (8 April to 18 December 2015). A follow-up of 4&#x02009;months is presented except for the repeated-measures model, survival and health service utilisation (8&#x02009;months) and study flow (10&#x02009;months).</p><sec id="section19-0269216318763225"><title>Feasibility measures</title><p><xref ref-type="table" rid="table1-0269216318763225">Table 1</xref> shows the patient flow. One UCG participant consented for every 2.8 screened versus 1 per 1.4 CTG screened. Fewer in the CTG died before approach (0.08% vs 16%) or declined invitation (17% vs 37%).</p><table-wrap id="table1-0269216318763225" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient flow.</p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">CTG, <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">UCG, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Screening</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">94</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Declined</td><td rowspan="1" colspan="1">11 (17)</td><td rowspan="1" colspan="1">35 (37)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Died before approach</td><td rowspan="1" colspan="1">5 (0.08)</td><td rowspan="1" colspan="1">15 (16)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unable to consent</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Admitted to hospital</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">43/62 (69)</td><td rowspan="1" colspan="1">34/94 (36)</td></tr><tr><td colspan="3" rowspan="1">Attrition following baseline</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Died</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Withdrew consent</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Deterioration</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Failed to attend</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">2-month follow-up</td><td rowspan="1" colspan="1">36/43 (84)</td><td rowspan="1" colspan="1">30/34 (88)</td></tr><tr><td colspan="3" rowspan="1">Attrition following 2&#x02009;months</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Died</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Withdrew consent</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Deterioration</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Failed to attend</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">4-month follow-up</td><td rowspan="1" colspan="1">32/43 (74)</td><td rowspan="1" colspan="1">24/34 (71)</td></tr><tr><td colspan="3" rowspan="1">Longer term follow-up for those recruited earlier in the study</td></tr><tr><td rowspan="1" colspan="1">&#x02003;6-month follow-up</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;8-month follow-up</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">5</td></tr><tr><td colspan="3" rowspan="1">Patient status at 10-month follow-up</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Attended</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Died</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Withdrew consent</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Not possible<sup>a</sup></td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lost to follow up</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-0269216318763225"><p>CTG: caring together group; UCG: usual care group.</p></fn><fn id="table-fn2-0269216318763225"><label>*</label><p>Patients recruited later in the study would not have sufficient follow-up time to complete visits beyond 4&#x02009;months after the recruitment date.</p></fn></table-wrap-foot></table-wrap><p>Most attrition was due to death or deterioration; those providing follow-up data had better performance status, symptom scores and quality of life (QoL) at baseline (data available). Data quality was otherwise good (<xref ref-type="table" rid="table2-0269216318763225">Tables 2</xref> and <xref ref-type="table" rid="table3-0269216318763225">3</xref>).</p><table-wrap id="table2-0269216318763225" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Outcomes at 4&#x02009;months.</p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Values at 4&#x02009;months</th><th align="left" colspan="3" rowspan="1">Change from baseline at 4&#x02009;months</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CTG, <italic>N</italic>&#x02009;=&#x02009;32</td><td rowspan="1" colspan="1">UCG, <italic>N</italic>&#x02009;=&#x02009;24</td><td rowspan="1" colspan="1"><italic>P</italic> value</td><td rowspan="1" colspan="1">CTG, <italic>N</italic>&#x02009;=&#x02009;32</td><td rowspan="1" colspan="1">UCG, <italic>N</italic>&#x02009;=&#x02009;24</td><td rowspan="1" colspan="1"><italic>P</italic> value</td></tr><tr><td colspan="7" rowspan="1">Health status and QoL</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MD, <italic>n</italic></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AKPS, median (IQR)</td><td rowspan="1" colspan="1">65 (60, 70)</td><td rowspan="1" colspan="1">60 (60, 70)</td><td rowspan="1" colspan="1">0.790<xref ref-type="table-fn" rid="table-fn4-0269216318763225">**</xref></td><td rowspan="1" colspan="1">0 (0, 0)</td><td rowspan="1" colspan="1">0 (&#x02013;10, 0)</td><td rowspan="1" colspan="1">0.687<xref ref-type="table-fn" rid="table-fn4-0269216318763225">**</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;MD, <italic>n</italic></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EQ-5D, mean (SD)</td><td rowspan="1" colspan="1">0.586 (0.227)</td><td rowspan="1" colspan="1">0.663 (0.250)</td><td rowspan="1" colspan="1">0.255</td><td rowspan="1" colspan="1">0.1 (0.2)</td><td rowspan="1" colspan="1">0.1 (0.3)</td><td rowspan="1" colspan="1">0.385<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">MD, <italic>n</italic></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">EQ-5D VAS, mean (SD)</td><td rowspan="1" colspan="1">56.2 (22.0)</td><td rowspan="1" colspan="1">61.7 (23.6)</td><td rowspan="1" colspan="1">0.386</td><td rowspan="1" colspan="1">3.5 (28.6)</td><td rowspan="1" colspan="1">&#x02013;4.0 (22.6)</td><td rowspan="1" colspan="1">0.901<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">KCCQ-12 score, mean (SD)</td><td rowspan="1" colspan="1">42.25 (21.71)</td><td rowspan="1" colspan="1">52.92 (24.40)</td><td rowspan="1" colspan="1">0.068</td><td rowspan="1" colspan="1">5.7 (20.3)</td><td rowspan="1" colspan="1">12.4 (25.2)</td><td rowspan="1" colspan="1">0.064<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td colspan="7" rowspan="1">Symptoms</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ESAS-r score, mean (SD)</td><td rowspan="1" colspan="1">39.23 (16.84)</td><td rowspan="1" colspan="1">28.09 (17.51)</td><td rowspan="1" colspan="1">0.022</td><td rowspan="1" colspan="1">&#x02212;1.5 (14.8)</td><td rowspan="1" colspan="1">&#x02212;5.6 (16.6)</td><td rowspan="1" colspan="1">0.046<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;MD, <italic>n</italic></td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HADS&#x02013;anxiety, mean (SD)</td><td rowspan="1" colspan="1">5.7 (4.3)</td><td rowspan="1" colspan="1">4.0 (5.4)</td><td rowspan="1" colspan="1">0.232</td><td rowspan="1" colspan="1">&#x02212;2.0 (3.6)</td><td rowspan="1" colspan="1">&#x02212;3.3 (3.7)</td><td rowspan="1" colspan="1">0.103<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;HADS&#x02013;depression, mean (SD)</td><td rowspan="1" colspan="1">6.8 (4.3)</td><td rowspan="1" colspan="1">5.8 (4.3)</td><td rowspan="1" colspan="1">0.408</td><td rowspan="1" colspan="1">&#x02212;0.5 (3.8)</td><td rowspan="1" colspan="1">&#x02212;0.5 (4.1)</td><td rowspan="1" colspan="1">0.679<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr><tr><td colspan="7" rowspan="1">Caregivers</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Caregivers, <italic>n</italic> (MD)</td><td rowspan="1" colspan="1">14 (1)</td><td rowspan="1" colspan="1">2 (3)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">14 (1)</td><td rowspan="1" colspan="1">2 (3)</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Zarit caregiver, mean (SD)</td><td rowspan="1" colspan="1">10.7 (6.4)</td><td rowspan="1" colspan="1">3.5 (2.1)</td><td rowspan="1" colspan="1">0.027</td><td rowspan="1" colspan="1">0.1 (3.1)</td><td rowspan="1" colspan="1">&#x02013;4.0 (2.8)</td><td rowspan="1" colspan="1">0.106<xref ref-type="table-fn" rid="table-fn4-0269216318763225">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-0269216318763225"><p>CTG: caring together group; UCG: usual care group; QoL: quality of life; MD: missing data; SD: standard deviation; N: number; IQR: inter-quartile range; AKPS: Australian Karnofsky Performance Scale; EQ-5D: EuroQol-5 dimension scale; ESAS-r: Edmonton Symptom Assessment Scale &#x02013; revised; KCCQ-12: Kansas City Cardiomyopathy Questionnaire; HADS: Hospital Anxiety and Depression Scale.</p></fn><fn id="table-fn4-0269216318763225"><label>*</label><p>Adjusted for baseline; **Wilcoxon&#x02013;Mann&#x02013;Whitney test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3-0269216318763225" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Outcomes at 4&#x02009;months regarding understanding and anticipatory care planning.</p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">CTG, <italic>N</italic>&#x02009;=&#x02009;32</th><th align="left" rowspan="1" colspan="1">UCG, <italic>N</italic>&#x02009;=&#x02009;24</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Understanding and anticipatory care planning</td></tr><tr><td rowspan="1" colspan="1">Missing data (excluding drop-outs)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Patients&#x02019; understanding of care, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="table-fn7-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Not at all</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;A little</td><td rowspan="1" colspan="1">4 (13.3)</td><td rowspan="1" colspan="1">11 (45.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Fairly well</td><td rowspan="1" colspan="1">9 (30.0)</td><td rowspan="1" colspan="1">10 (41.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Very well</td><td rowspan="1" colspan="1">15 (50.0)</td><td rowspan="1" colspan="1">3 (12.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Completely</td><td rowspan="1" colspan="1">2 (6.7)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Missing data (excluding drop-outs), <italic>n</italic></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">DNAR-CPR: Evidence of discussion with patient in case notes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">28 (77.8)</td><td rowspan="1" colspan="1">7 (24.1)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">DNAR-CPR: Evidence of discussion with carer in case notes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">21 (58.3)</td><td rowspan="1" colspan="1">4 (13.8)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">CARE: Evidence of discussion with carer in case notes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">29 (80.6)</td><td rowspan="1" colspan="1">9 (31.0)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">CARE: Evidence of discussion with patient in case, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">23 (63.9)</td><td rowspan="1" colspan="1">4 (14.3)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Documented preferred place of care<sup><xref ref-type="table-fn" rid="table-fn6-0269216318763225">a</xref></sup>, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.184</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Home</td><td rowspan="1" colspan="1">24 (82.8)</td><td rowspan="1" colspan="1">6 (66.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Care home</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (11.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hospital</td><td rowspan="1" colspan="1">5 (17.2)</td><td rowspan="1" colspan="1">2 (22.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hospice</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-0269216318763225"><p>CTG: caring together group; UCG: usual care group; MD: missing data; <italic>N</italic>: number; DNAR-CPR: do not attempt cardiopulmonary resuscitation.</p></fn><fn id="table-fn6-0269216318763225"><label>a</label><p>Number (%) of those who provided a response to this question (CTG: <italic>n</italic>&#x02009;=&#x02009;29; UCG: <italic>n</italic>&#x02009;=&#x02009;9).</p></fn><fn id="table-fn7-0269216318763225"><label>*</label><p>Wilcoxon&#x02013;Mann&#x02013;Whitney test.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="section20-0269216318763225"><title>Baseline characteristics</title><p>Both groups were on optimal tolerated cardiac treatment.</p><p>There were clinically important between-group differences (<xref ref-type="table" rid="table4-0269216318763225">Tables 4</xref> and <xref ref-type="table" rid="table5-0269216318763225">5</xref>). Nearly all UCG participants had HFrEF, but half of the CTG participants had HFnEF (<xref ref-type="table" rid="table4-0269216318763225">Table 4</xref>). CTG patients had worse NYHA class, symptoms (ESAS-r) and quality of life (KCCQ-12), and less deprivation. Most CTG participants had ACP documented and better understanding.</p><table-wrap id="table4-0269216318763225" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Baseline demographic characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All patients, <italic>N</italic>&#x02009;=&#x02009;77</th><th align="left" rowspan="1" colspan="1">CTG, <italic>N</italic>&#x02009;=&#x02009;43</th><th align="left" rowspan="1" colspan="1">UCG, <italic>N</italic>&#x02009;=&#x02009;34</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MD</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Age in years, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">77.0 (11.9)<break/>33&#x02013;100</td><td rowspan="1" colspan="1">75.8 (12.3)<break/>33&#x02013;100</td><td rowspan="1" colspan="1">78.4 (11.3)<break/>54&#x02013;96</td><td rowspan="1" colspan="1">0.339</td></tr><tr><td rowspan="1" colspan="1">Gender: male, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">41 (53.2)</td><td rowspan="1" colspan="1">24 (55.8)</td><td rowspan="1" colspan="1">17 (50.0)</td><td rowspan="1" colspan="1">0.651</td></tr><tr><td rowspan="1" colspan="1">SIMD quintiles; MD, <italic>n</italic></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Most deprived, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">27 (36.0)</td><td rowspan="1" colspan="1">12 (29.3)</td><td rowspan="1" colspan="1">15 (44.1)</td><td rowspan="1" colspan="1">0.564</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">9 (12.0)</td><td rowspan="1" colspan="1">7 (17.1)</td><td rowspan="1" colspan="1">2 (5.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">9 (12.0)</td><td rowspan="1" colspan="1">5 (12.2)</td><td rowspan="1" colspan="1">4 (11.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">8 (10.7)</td><td rowspan="1" colspan="1">6 (14.6)</td><td rowspan="1" colspan="1">2 (5.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Least deprived</td><td rowspan="1" colspan="1">4 (5.3)</td><td rowspan="1" colspan="1">2 (4.9)</td><td rowspan="1" colspan="1">2 (5.9)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="5" rowspan="1">Hospital admissions</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Admitted due to HF within the past 6&#x02009;months, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">30 (39.0)</td><td rowspan="1" colspan="1">14 (32.6)</td><td rowspan="1" colspan="1">16 (47.1)</td><td rowspan="1" colspan="1">0.242</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Admitted to hospital in the past 1&#x02009;month, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">11 (14.3)</td><td rowspan="1" colspan="1">4 (9.3)</td><td rowspan="1" colspan="1">7 (20.6)</td><td rowspan="1" colspan="1">0.199</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Number of nights in hospital in the past 1&#x02009;month, <italic>n</italic> (SD)</td><td rowspan="1" colspan="1">6.3 (22.1)</td><td rowspan="1" colspan="1">4.5 (21.0)</td><td rowspan="1" colspan="1">8.6 (23.6)</td><td rowspan="1" colspan="1">0.429</td></tr><tr><td colspan="5" rowspan="1">NYHA status, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Class I</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0.067<xref ref-type="table-fn" rid="table-fn9-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Class II</td><td rowspan="1" colspan="1">3 (3.9)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (8.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Class III</td><td rowspan="1" colspan="1">70 (90.9)</td><td rowspan="1" colspan="1">40 (93.0)</td><td rowspan="1" colspan="1">30 (88.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Class IV</td><td rowspan="1" colspan="1">4 (5.2)</td><td rowspan="1" colspan="1">3 (7.0)</td><td rowspan="1" colspan="1">1 (2.9)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="5" rowspan="1">Echocardiography</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Echo available, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">62 (80.5);</td><td rowspan="1" colspan="1">32 (74.4)</td><td rowspan="1" colspan="1">30 (88.2)</td><td rowspan="1" colspan="1">0.156</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Echo LVSD, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">45 (72.6)</td><td rowspan="1" colspan="1">16 (50.0)</td><td rowspan="1" colspan="1">29 (96.7)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Ejection fraction; MD, <italic>n</italic></td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean, % (SD)</td><td rowspan="1" colspan="1">42.1 (16.4)</td><td rowspan="1" colspan="1">46.5 (19.4)</td><td rowspan="1" colspan="1">37.6 (11.3)</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td colspan="5" rowspan="1">Urea and electrolytes</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sodium; MD, <italic>n</italic></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean, mmol/l (SD)<break/>Range</td><td rowspan="1" colspan="1">139 (3.3)<break/>130&#x02013;148</td><td rowspan="1" colspan="1">138 (3.9)<break/>130&#x02013;148</td><td rowspan="1" colspan="1">139 (2.5)<break/>134&#x02013;144</td><td rowspan="1" colspan="1">0.323</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Potassium; MD, <italic>n</italic></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean, mmol/l (SD)<break/>Range</td><td rowspan="1" colspan="1">4.2 (0.4)<break/>3.0&#x02013;5.1</td><td rowspan="1" colspan="1">4.2 (0.4)<break/>3.0&#x02013;5.1</td><td rowspan="1" colspan="1">4.3 (0.5)<break/>3.2&#x02013;5.1</td><td rowspan="1" colspan="1">0.869</td></tr><tr><td rowspan="1" colspan="1">&#x02003;eGFR; MD, <italic>n</italic></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean, mL/min (SD)<break/>Range</td><td rowspan="1" colspan="1">46.4 (14.4)<break/>10&#x02013;77</td><td rowspan="1" colspan="1">46.7 (15.3)<break/>10&#x02013;60</td><td rowspan="1" colspan="1">46.0 (13.5)<break/>20&#x02013;77</td><td rowspan="1" colspan="1">0.834</td></tr><tr><td rowspan="1" colspan="1">Charlson comorbidity index; median (IQR)<break/>Range</td><td rowspan="1" colspan="1">7 (6, 8)<break/>2&#x02013;14</td><td rowspan="1" colspan="1">7 (6, 8)<break/>2&#x02013;14</td><td rowspan="1" colspan="1">8 (6, 9)<break/>4&#x02013;12</td><td rowspan="1" colspan="1">0.029<xref ref-type="table-fn" rid="table-fn9-0269216318763225">*</xref></td></tr><tr><td colspan="5" rowspan="1">Cardiac medication, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ACE inhibitor</td><td rowspan="1" colspan="1">28 (36.4)</td><td rowspan="1" colspan="1">12 (27.9)</td><td rowspan="1" colspan="1">16 (47.1)</td><td rowspan="1" colspan="1">0.099</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ARB</td><td rowspan="1" colspan="1">11 (14.3)</td><td rowspan="1" colspan="1">6 (14.0)</td><td rowspan="1" colspan="1">5 (14.7)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blocker</td><td rowspan="1" colspan="1">47 (61.0)</td><td rowspan="1" colspan="1">21 (48.8)</td><td rowspan="1" colspan="1">26 (76.5)</td><td rowspan="1" colspan="1">0.019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Aldosterone blocker</td><td rowspan="1" colspan="1">25 (35.7)</td><td rowspan="1" colspan="1">18 (48.6)</td><td rowspan="1" colspan="1">7 (21.2)</td><td rowspan="1" colspan="1">0.024</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Aldosterone blocker: spironolactone</td><td rowspan="1" colspan="1">21 (27.3)</td><td rowspan="1" colspan="1">15 (34.9)</td><td rowspan="1" colspan="1">6 (17.6)</td><td rowspan="1" colspan="1">0.124</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Aldosterone blocker: eplerenone</td><td rowspan="1" colspan="1">4 (5.2)</td><td rowspan="1" colspan="1">3 (7.0)</td><td rowspan="1" colspan="1">1 (2.9)</td><td rowspan="1" colspan="1">0.626</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn8-0269216318763225"><p>CTG: caring together group; UCG: usual care group; MD: missing data; SD: standard deviation; <italic>N</italic>: number; SIMD: standardised index of multiple deprivation; HF: heart failure; IQR: inter-quartile range; NYHA: New York Heart Association; LVSD: left ventricular systolic dysfunction; eGFR: estimated glomerular filtration rate; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.</p></fn><fn id="table-fn9-0269216318763225"><label>*</label><p>Wilcoxon&#x02013;Mann&#x02013;Whitney test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5-0269216318763225" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Baseline outcome measures.</p></caption><alternatives><graphic xlink:href="10.1177_0269216318763225-table5"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">No missing data</th><th align="left" rowspan="1" colspan="1">All, <italic>N</italic>&#x02009;=&#x02009;77</th><th align="left" rowspan="1" colspan="1">CTG, <italic>N</italic>&#x02009;=&#x02009;43</th><th align="left" rowspan="1" colspan="1">UCG, <italic>N</italic>&#x02009;=&#x02009;34</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Health status and quality of life</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EQ-5D score, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">0.524 (0.288)<break/>&#x02013;0.170 to 0.951</td><td rowspan="1" colspan="1">0.517 (0.318)<break/>&#x02013;0.170 to 0.951</td><td rowspan="1" colspan="1">0.532 (0.250)<break/>&#x02013;0.027 to 0.951</td><td rowspan="1" colspan="1">0.828</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EQ-5D VAS, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">55.2 (26.0)<break/>5 to 100</td><td rowspan="1" colspan="1">50.5 (26.8)<break/>5 to 99</td><td rowspan="1" colspan="1">61.2 (24.0)<break/>10 to 100</td><td rowspan="1" colspan="1">0.070</td></tr><tr><td rowspan="1" colspan="1">&#x02003;KCCQ-12 score, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">37.36 (26.47)<break/>0 to 100</td><td rowspan="1" colspan="1">35.37 (25.57)<break/>0 to 88</td><td rowspan="1" colspan="1">39.89 (27.75)<break/>0 to 100</td><td rowspan="1" colspan="1">0.465</td></tr><tr><td colspan="5" rowspan="1">Symptoms</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ESAS-r score, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">39.81 (21.14)<break/>0 to 82</td><td rowspan="1" colspan="1">43.45 (21.56)<break/>4 to 82</td><td rowspan="1" colspan="1">35.21 (19.96)<break/>0 to 78</td><td rowspan="1" colspan="1">0.087</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HADS&#x02013;anxiety, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">7.7 (5.3)<break/>0 to 20</td><td rowspan="1" colspan="1">7.8 (4.9)<break/>0 to 19</td><td rowspan="1" colspan="1">7.5 (5.9)<break/>0 to 20</td><td rowspan="1" colspan="1">0.786</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HADS&#x02013;depression, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">7.8 (4.5)<break/>0 to 17</td><td rowspan="1" colspan="1">8.5 (4.6)<break/>0 to 17</td><td rowspan="1" colspan="1">6.9 (4.4)<break/>0 to 16</td><td rowspan="1" colspan="1">0.140</td></tr><tr><td colspan="5" rowspan="1">Caregivers</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Zarit caregiver, mean (SD)<break/>Range</td><td rowspan="1" colspan="1">11.0 (5.3)<break/>0 to 20</td><td rowspan="1" colspan="1">11.2 (5.3)<break/>0 to 19</td><td rowspan="1" colspan="1">10.6 (5.8)<break/>2 to 20</td><td rowspan="1" colspan="1">0.820</td></tr><tr><td colspan="5" rowspan="1">Understanding and advance care planning</td></tr><tr><td colspan="5" rowspan="1">Patients&#x02019; understanding of care, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Not at all</td><td rowspan="1" colspan="1">5 (6.5)</td><td rowspan="1" colspan="1">1 (2.3)</td><td rowspan="1" colspan="1">4 (11.8)</td><td rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="table-fn11-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;A little</td><td rowspan="1" colspan="1">32 (41.6)</td><td rowspan="1" colspan="1">14 (32.6)</td><td rowspan="1" colspan="1">18 (52.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Fairly well</td><td rowspan="1" colspan="1">24 (31.2)</td><td rowspan="1" colspan="1">15 (34.9)</td><td rowspan="1" colspan="1">9 (26.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Very well</td><td rowspan="1" colspan="1">15 (19.5)</td><td rowspan="1" colspan="1">12 (27.9)</td><td rowspan="1" colspan="1">3 (8.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Completely</td><td rowspan="1" colspan="1">1 (1.3)</td><td rowspan="1" colspan="1">1 (2.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">DNAR-CPR: Evidence of discussion with patient in case notes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">38 (49.4)</td><td rowspan="1" colspan="1">33 (76.7)</td><td rowspan="1" colspan="1">5 (14.7)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">DNAR-CPR: Evidence of discussion with carer in case notes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">24 (31.2)</td><td rowspan="1" colspan="1">22 (51.2)</td><td rowspan="1" colspan="1">2 (5.9</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Documented ACP discussion (patient), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">35 (45.5)</td><td rowspan="1" colspan="1">29 (67.4)</td><td rowspan="1" colspan="1">6 (17.6)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Documented ACP discussion (carer), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">26 (33.8)</td><td rowspan="1" colspan="1">23 (53.5)</td><td rowspan="1" colspan="1">3 (8.8)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="5" rowspan="1">Documented preferred place of care, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Home</td><td rowspan="1" colspan="1">30 (85.7)</td><td rowspan="1" colspan="1">25 (86.2)</td><td rowspan="1" colspan="1">5 (83.3)</td><td rowspan="1" colspan="1">0.634<xref ref-type="table-fn" rid="table-fn11-0269216318763225">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Care home</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hospital</td><td rowspan="1" colspan="1">4 (11.4)</td><td rowspan="1" colspan="1">3 (10.3)</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hospice</td><td rowspan="1" colspan="1">1 (2.9)</td><td rowspan="1" colspan="1">1 (3.4)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn10-0269216318763225"><p>CTG: caring together group; UCG: usual care group; SD: standard deviation; <italic>N</italic>: number; EQ-5D: EuroQol-5 dimension scale; ESAS-r: Edmonton Symptom Assessment Scale &#x02013; revised; KCCQ-12: Kansas City Cardiomyopathy Questionnaire; HADS: Hospital Anxiety and Depression Scale; DNAR-CPR: do not attempt cardiopulmonary resuscitation; ACP: anticipatory care plan.</p></fn><fn id="table-fn11-0269216318763225"><label>*</label><p>Wilcoxon&#x02013;Mann&#x02013;Whitney test.</p></fn></table-wrap-foot></table-wrap><p>More UCG participants had prior admissions (47.1% vs 32.6%). All CTG participants had attended CT at least once (median: 8&#x02009;months; inter-quartile range (IQR): 2&#x02013;21&#x02009;months).</p><sec id="section21-0269216318763225"><title>Group comparison at follow-up</title><p>Overall, the ESAS-r and KCCQ-12 scores improved. At 4&#x02009;months, adjusted symptom improvement was greater in the UCG (0.046). ACP documentation and understanding remained better in the CTG (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Two UCG participants were transferred to CTG, but there were no differences in the PP analysis findings.</p><p>CTG participants had fewer nights in hospital, but more GP visits (eTable 1). CT participants commented on excellent, individually tailored, coordinated care. UCG participants commented on fragmented care, poor communication and different unfamiliar doctors.</p><p>There was no between-group difference in survival (eFigure 1 online; time to death).</p></sec><sec id="section22-0269216318763225"><title>Repeated-measures model</title><p>There were no between-group differences in EQ-5D-5L (<italic>p</italic>&#x02009;=&#x02009;0.50) or KCCQ-12 (<italic>p</italic>&#x02009;=&#x02009;0.08) at 4&#x02009;months after adjustment for age, sex or baseline individual ESAS-r (eFigure 2 online).</p></sec><sec id="section23-0269216318763225"><title>Health service use and costs</title><p>Differences in health service use are shown in eTable 1. Estimated differences in costs show that the average healthcare costs reduced by &#x000a3;785 in CTG. This is statistically insignificant and subject to considerable uncertainty.</p></sec><sec id="section24-0269216318763225"><title>Sample size calculation for the main trial</title><p>Important clinical differences for KCCQ-12<sup><xref rid="bibr40-0269216318763225" ref-type="bibr">40</xref></sup> and ESAS (breathlessness)<sup><xref rid="bibr41-0269216318763225" ref-type="bibr">41</xref></sup> were used. UCG was taken as the population of interest and ESAS (breathlessness) as the symptom most highly correlated with KCCQ-12 (data available). eTable 2 shows the estimated sample sizes (80% and 90% power; alpha 0.05). To detect a difference of 10.5 points (KCCQ-12) and 1 point (ESAS breathlessness), the sample sizes of 176 and 141, respectively, are needed (30% attrition; 252 and 202).</p></sec></sec><sec sec-type="discussion" id="section25-0269216318763225"><title>Discussion</title><sec id="section26-0269216318763225"><title>Feasibility outcomes</title><p>It is feasible to recruit and collect data for a clinical study. As reported previously in palliative studies,<sup><xref rid="bibr42-0269216318763225" ref-type="bibr">42</xref></sup> attrition was high (27% at 4&#x02009;months) mostly due to death or deterioration. Further feasibility work should test the willingness to be randomised.</p></sec><sec id="section27-0269216318763225"><title>Strengths and limitations</title><p>This the first study to provide patient report and cost-effectiveness data from a cardiology-led palliative heart failure service. Other studies report the components only (ACP, patient-centred decisions)<sup><xref rid="bibr43-0269216318763225" ref-type="bibr">43</xref></sup> or historical controls.<sup><xref rid="bibr27-0269216318763225" ref-type="bibr">27</xref></sup></p><p>The major limitations are as follows: (1) non-randomisation, (2) cost neutrality was assumed and opportunity costs were not considered, (3) missing data and (4) CT participants were already receiving cardiology-led palliative care (possible underestimated benefit).</p></sec><sec id="section28-0269216318763225"><title>What this study adds</title><p>This study provides useful feasibility and early safety data; the UCG did not appear to be disadvantaged in terms of survival or 4-month outcomes. Willingness to be randomised was not tested but could be built into a pilot embedded into a phase III trial. Recruitment appeared to be easier from patients known to the research team (UCG). This should be taken into account when researchers are dependent on other clinical teams to identify potential participants although eligible patients may be more inclined to participate in an intervention trial.</p><p>A recent US statement<sup><xref rid="bibr7-0269216318763225" ref-type="bibr">7</xref></sup> encourages problem-driven palliative care independent of prognosis, citing benefits as improved patient/carer understanding, symptoms/suffering relief, patient-centred decision-making, improved communication, better ACP and bereavement support. Although the study was not designed to assess effectiveness, the data on patient understanding, ACP documentation, fewer nights in hospital and being shifted from secondary to community care show promise &#x02013; consistent with Component 5 (<xref ref-type="table" rid="table6-0269216318763225">Box 1</xref>).</p></sec></sec><sec sec-type="conclusions" id="section29-0269216318763225"><title>Conclusion</title><p>A clinical trial investigating the cost-effectiveness of cardiology-led heart failure palliative care is feasible. A future trial should recruit from usual community-based care eligible for but not referred to cardiology palliative care, and identify those needing more intensive palliative care.</p></sec></body><back><ack><p>The authors wish to thank Professor Fliss Murtagh, University of Hull, for valuable advice with regard to the final revision. M.J., K.H. and Y.M. conceived the study, M.J., P.M., A.M., C.G. and A.B. designed the protocol. P.M., A.M. and C.G. conducted the analysis. All the authors contributed to the interpretation of findings. M.J. wrote the first draft and all the authors contributed to subsequent drafts and approved the final manuscript.</p></ack><fn-group><fn fn-type="other"><p><bold>Data sharing:</bold> The author for correspondence may be contacted regarding access to anonymised data. Data that are not shown in the paper but are available are provided in the manuscript.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold> The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: K.H. and Y.M. were funded by CTPartners. The other authors declare no conflict of interest.</p></fn><fn fn-type="other"><p><bold>Ethics and consent:</bold> Ethical (NRES Committee London &#x02013; Camberwell St Giles. REF 14/LO/1813; 07.10.2014) and institutional approvals were obtained prior to recruitment. Participants gave written informed consent.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was funded by the British Heart Foundation and Marie Curie.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Miriam J Johnson <inline-graphic xlink:href="10.1177_0269216318763225-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-6204-9158">https://orcid.org/0000-0001-6204-9158</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-0269216318763225"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>S</given-names></name><name><surname>Gott</surname><given-names>M</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Prevalence of symptoms in a community-based sample of heart failure patients</article-title>. <source>J Pain Symptom Manage</source>
<year>2006</year>; <volume>32</volume>(<issue>3</issue>): <fpage>208</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">16939845</pub-id></mixed-citation></ref><ref id="bibr2-0269216318763225"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>SA</given-names></name><name><surname>Boyd</surname><given-names>K</given-names></name><name><surname>Kendall</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community</article-title>. <source>BMJ</source>
<year>2002</year>; <volume>325</volume>(<issue>7370</issue>): <fpage>929</fpage>.<pub-id pub-id-type="pmid">12399341</pub-id></mixed-citation></ref><ref id="bibr3-0269216318763225"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>SA</given-names></name><name><surname>Kendall</surname><given-names>M</given-names></name><name><surname>Boyd</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Exploring the spiritual needs of people dying of lung cancer or heart failure: a prospective qualitative interview study of patients and their carers</article-title>. <source>Palliat Med</source>
<year>2004</year>; <volume>18</volume>(<issue>1</issue>): <fpage>39</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">14982206</pub-id></mixed-citation></ref><ref id="bibr4-0269216318763225"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pantilat</surname><given-names>SZ</given-names></name><name><surname>O&#x02019;Riordan</surname><given-names>DL</given-names></name><name><surname>Dibble</surname><given-names>SL</given-names></name><etal>et al</etal></person-group>
<article-title>Longitudinal assessment of symptom severity among hospitalized elders diagnosed with cancer, heart failure, and chronic obstructive pulmonary disease</article-title>. <source>J Hosp Med</source>
<year>2012</year>; <volume>7</volume>(<issue>7</issue>): <fpage>567</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">22371388</pub-id></mixed-citation></ref><ref id="bibr5-0269216318763225"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rogers</surname><given-names>A</given-names></name><name><surname>Addington-Hall</surname><given-names>JM</given-names></name><name><surname>McCoy</surname><given-names>AS</given-names></name><etal>et al</etal></person-group>
<article-title>A qualitative study of chronic heart failure patients&#x02019; understanding of their symptoms and drug therapy</article-title>. <source>Eur J Heart Fail</source>
<year>2002</year>; <volume>4</volume>(<issue>3</issue>): <fpage>283</fpage>&#x02013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">12034153</pub-id></mixed-citation></ref><ref id="bibr6-0269216318763225"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rogers</surname><given-names>AE</given-names></name><name><surname>Addington-Hall</surname><given-names>JM</given-names></name><name><surname>Abery</surname><given-names>AJ</given-names></name><etal>et al</etal></person-group>
<article-title>Knowledge and communication difficulties for patients with chronic heart failure: qualitative study</article-title>. <source>BMJ</source>
<year>2000</year>; <volume>321</volume>(<issue>7261</issue>): <fpage>605</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">10977838</pub-id></mixed-citation></ref><ref id="bibr7-0269216318763225"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braun</surname><given-names>LT</given-names></name><name><surname>Grady</surname><given-names>KL</given-names></name><name><surname>Kutner</surname><given-names>JS</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care and cardiovascular disease and stroke: a policy statement from the American Heart Association/American Stroke Association</article-title>. <source>Circulation</source>
<year>2016</year>; <volume>134</volume>: <fpage>e198</fpage>&#x02013;<lpage>e225</lpage>.<pub-id pub-id-type="pmid">27503067</pub-id></mixed-citation></ref><ref id="bibr8-0269216318763225"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Howlett</surname><given-names>JG</given-names></name><name><surname>McKelvie</surname><given-names>RS</given-names></name><name><surname>Costigan</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs</article-title>. <source>Can J Cardiol</source>
<year>2010</year>; <volume>26</volume>(<issue>4</issue>): <fpage>185</fpage>&#x02013;<lpage>202</lpage>.</mixed-citation></ref><ref id="bibr9-0269216318763225"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaarsma</surname><given-names>T</given-names></name><name><surname>Beattie</surname><given-names>JM</given-names></name><name><surname>Ryder</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology</article-title>. <source>Eur J Heart Fail</source>
<year>2009</year>; <volume>11</volume>(<issue>5</issue>): <fpage>433</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">19386813</pub-id></mixed-citation></ref><ref id="bibr10-0269216318763225"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whellan</surname><given-names>DJ</given-names></name><name><surname>Goodlin</surname><given-names>SJ</given-names></name><name><surname>Dickinson</surname><given-names>MG</given-names></name><etal>et al</etal></person-group>
<article-title>End-of-life care in patients with heart failure</article-title>. <source>J Card Fail</source>
<year>2014</year>; <volume>20</volume>(<issue>2</issue>): <fpage>121</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">24556532</pub-id></mixed-citation></ref><ref id="bibr11-0269216318763225"><label>11</label><mixed-citation publication-type="web">
<collab>National survey of patient activity data for specialist palliative care services: MDS full report for the year 2013&#x02013;2014</collab>, <ext-link ext-link-type="uri" xlink:href="http://www.endoflifecare-intelligence.org.uk/resources/publications/mdsreport2014">http://www.endoflifecare-intelligence.org.uk/resources/publications/mdsreport2014</ext-link></mixed-citation></ref><ref id="bibr12-0269216318763225"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barclay</surname><given-names>S</given-names></name><name><surname>Momen</surname><given-names>N</given-names></name><name><surname>Case-Upton</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>End-of-life care conversations with heart failure patients: a systematic literature review and narrative synthesis</article-title>. <source>Br J Gen Pract</source>
<year>2011</year>; <volume>61</volume>(<issue>582</issue>): <fpage>e49</fpage>&#x02013;<lpage>e62</lpage>.<pub-id pub-id-type="pmid">21401993</pub-id></mixed-citation></ref><ref id="bibr13-0269216318763225"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gadoud</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>E</given-names></name><name><surname>Macleod</surname><given-names>U</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care among heart failure patients in primary care: a comparison to cancer patients using English family practice data</article-title>. <source>PLoS ONE</source>
<year>2014</year>; <volume>9</volume>(<issue>11</issue>): <fpage>e113188</fpage>.<pub-id pub-id-type="pmid">25423169</pub-id></mixed-citation></ref><ref id="bibr14-0269216318763225"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N</given-names></name><name><surname>Cavers</surname><given-names>D</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Are UK primary care teams formally identifying patients for palliative care before they die?</article-title>
<source>Br J Gen Pract</source>
<year>2012</year>; <volume>62</volume>(<issue>598</issue>): <fpage>e344</fpage>&#x02013;<lpage>e352</lpage>.<pub-id pub-id-type="pmid">22546594</pub-id></mixed-citation></ref><ref id="bibr15-0269216318763225"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Selman</surname><given-names>L</given-names></name><name><surname>Harding</surname><given-names>R</given-names></name><name><surname>Beynon</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Improving end-of-life care for patients with chronic heart failure: &#x02018;Let&#x02019;s hope it&#x02019;ll get better, when I know in my heart of hearts it won&#x02019;t&#x02019;</article-title>. <source>Heart</source>
<year>2007</year>; <volume>93</volume>(<issue>8</issue>): <fpage>963</fpage>&#x02013;<lpage>967</lpage>.<pub-id pub-id-type="pmid">17309905</pub-id></mixed-citation></ref><ref id="bibr16-0269216318763225"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brannstrom</surname><given-names>M</given-names></name><name><surname>Boman</surname><given-names>K.</given-names></name></person-group>
<article-title>Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study</article-title>. <source>Eur J Heart Fail</source>
<year>2014</year>; <volume>16</volume>(<issue>10</issue>): <fpage>1142</fpage>&#x02013;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">25159126</pub-id></mixed-citation></ref><ref id="bibr17-0269216318763225"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sidebottom</surname><given-names>AC</given-names></name><name><surname>Jorgenson</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial</article-title>. <source>J Palliat Med</source>
<year>2015</year>; <volume>18</volume>(<issue>2</issue>): <fpage>134</fpage>&#x02013;<lpage>142</lpage>.<pub-id pub-id-type="pmid">25479182</pub-id></mixed-citation></ref><ref id="bibr18-0269216318763225"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>FK</given-names></name><name><surname>Ng</surname><given-names>AY</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of a transitional palliative care model on patients with end-stage heart failure: a randomised controlled trial</article-title>. <source>Heart</source>
<year>2016</year>; <volume>11</volume>: <fpage>1100</fpage>&#x02013;<lpage>1108</lpage>.</mixed-citation></ref><ref id="bibr19-0269216318763225"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rogers</surname><given-names>JG</given-names></name><name><surname>Patel</surname><given-names>CB</given-names></name><name><surname>Mentz</surname><given-names>RJ</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial</article-title>. <source>J Am Coll Cardiol</source>
<year>2017</year>; <volume>70</volume>(<issue>3</issue>): <fpage>331</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">28705314</pub-id></mixed-citation></ref><ref id="bibr20-0269216318763225"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sahlen</surname><given-names>KG</given-names></name><name><surname>Boman</surname><given-names>K</given-names></name><name><surname>Brannstrom</surname><given-names>M.</given-names></name></person-group>
<article-title>A cost-effectiveness study of person-centered integrated heart failure and palliative home care: based on a randomized controlled trial</article-title>. <source>Palliat Med</source>
<year>2016</year>; <volume>30</volume>(<issue>3</issue>): <fpage>296</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">26603186</pub-id></mixed-citation></ref><ref id="bibr21-0269216318763225"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>FKY</given-names></name><name><surname>So</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>AYM</given-names></name><etal>et al</etal></person-group>
<article-title>Cost-effectiveness of a transitional home-based palliative care program for patients with end-stage heart failure</article-title>. <source>Palliat Med</source>
<year>2017</year>; <volume>32</volume>: <fpage>476</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">28434275</pub-id></mixed-citation></ref><ref id="bibr22-0269216318763225"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidson</surname><given-names>PM</given-names></name><name><surname>Paull</surname><given-names>G</given-names></name><name><surname>Introna</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Integrated, collaborative palliative care in heart failure: the St. George Heart Failure Service experience 1999&#x02013;2002</article-title>. <source>J Cardiovasc Nurs</source>
<year>2004</year>; <volume>19</volume>(<issue>1</issue>): <fpage>68</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">14994784</pub-id></mixed-citation></ref><ref id="bibr23-0269216318763225"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quill</surname><given-names>TE</given-names></name><name><surname>Abernethy</surname><given-names>AP.</given-names></name></person-group>
<article-title>Generalist plus specialist palliative care&#x02013;creating a more sustainable model</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>(<issue>13</issue>): <fpage>1173</fpage>&#x02013;<lpage>1175</lpage>.<pub-id pub-id-type="pmid">23465068</pub-id></mixed-citation></ref><ref id="bibr24-0269216318763225"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daley</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>A.</given-names></name></person-group>
<article-title>Heart failure and palliative care services working in partnership: report of a new model of care</article-title>. <source>Palliat Med</source>
<year>2006</year>; <volume>20</volume>(<issue>6</issue>): <fpage>593</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="pmid">17060252</pub-id></mixed-citation></ref><ref id="bibr25-0269216318763225"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MJ</given-names></name><name><surname>Nunn</surname><given-names>A</given-names></name><name><surname>Hawkes</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Planning for end of life care in people with heart failure: experience of two integrated cardiology-palliative care</article-title>. <source>Br J Cardiol</source>
<year>2012</year>; <volume>19</volume>: <fpage>71</fpage>&#x02013;<lpage>75</lpage>.</mixed-citation></ref><ref id="bibr26-0269216318763225"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Parsons</surname><given-names>S</given-names></name><name><surname>Raw</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Achieving preferred place of death &#x02013; is it possible for patients with chronic heart failure?</article-title>
<source>Br J Cardiology</source>
<year>2009</year>; <volume>16</volume>: <fpage>194</fpage>&#x02013;<lpage>196</lpage>.</mixed-citation></ref><ref id="bibr27-0269216318763225"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pattenden</surname><given-names>JF</given-names></name><name><surname>Mason</surname><given-names>AR</given-names></name><name><surname>Lewin</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Collaborative palliative care for advanced heart failure: outcomes and costs from the &#x02018;Better Together&#x02019; pilot study</article-title>. <source>BMJ Support Palliat Care</source>
<year>2013</year>; <volume>3</volume>(<issue>1</issue>): <fpage>69</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="bibr28-0269216318763225"><label>28</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Bouamerane</surname><given-names>M-M</given-names></name><name><surname>Saunderson</surname><given-names>K</given-names></name><name><surname>Mair</surname><given-names>F.</given-names></name></person-group>
<source>Caring together manualisation report</source>. <publisher-loc>London</publisher-loc>: <publisher-name>British Heart Foundation; Marie Curie Cancer Care</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="bibr29-0269216318763225"><label>29</label><mixed-citation publication-type="book">
<collab>Research Advisory Group.</collab>
<source>Impact of programme: quantitative data</source>. <publisher-loc>London</publisher-loc>: <publisher-name>British Heart Foundation/Marie Curie Cancer Research</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="bibr30-0269216318763225"><label>30</label><mixed-citation publication-type="book">
<collab>The Criteria Committee of the New York Heart Association</collab>. <source>Nomenclature and criteria for diagnosis of diseases of the heart and great vessels</source>, <edition>6th ed.</edition>
<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Little, Brown and Company</publisher-name>, <year>1994</year>.</mixed-citation></ref><ref id="bibr31-0269216318763225"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abernethy</surname><given-names>AP</given-names></name><name><surname>Shelby-James</surname><given-names>T</given-names></name><name><surname>Fazekas</surname><given-names>BS</given-names></name><etal>et al</etal></person-group>
<article-title>The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]</article-title>. <source>BMC Palliat Care</source>
<year>2005</year>; <volume>4</volume>: <fpage>7</fpage>.<pub-id pub-id-type="pmid">16283937</pub-id></mixed-citation></ref><ref id="bibr32-0269216318763225"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Charlson</surname><given-names>M</given-names></name><name><surname>Szatrowski</surname><given-names>TP</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Validation of a combined comorbidity index</article-title>. <source>J Clin Epidemiol</source>
<year>1994</year>; <volume>47</volume>(<issue>11</issue>): <fpage>1245</fpage>&#x02013;<lpage>1251</lpage>.<pub-id pub-id-type="pmid">7722560</pub-id></mixed-citation></ref><ref id="bibr33-0269216318763225"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bruera</surname><given-names>E</given-names></name><name><surname>Kuehn</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group>
<article-title>The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients</article-title>. <source>J Palliat Care</source>
<year>1991</year>; <volume>7</volume>(<issue>2</issue>): <fpage>6</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1714502</pub-id></mixed-citation></ref><ref id="bibr34-0269216318763225"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>CP</given-names></name><name><surname>Porter</surname><given-names>CB</given-names></name><name><surname>Bresnahan</surname><given-names>DR</given-names></name><etal>et al</etal></person-group>
<article-title>Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure</article-title>. <source>J Am Coll Cardiol</source>
<year>2000</year>; <volume>35</volume>(<issue>5</issue>): <fpage>1245</fpage>&#x02013;<lpage>1255</lpage>.<pub-id pub-id-type="pmid">10758967</pub-id></mixed-citation></ref><ref id="bibr35-0269216318763225"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Gosch</surname><given-names>K</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>The KCCQ-12: a short version of the Kansas City Cardiomyopathy Questionnaire</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>
<year>2013</year>; <volume>6</volume>: <fpage>A248</fpage>.</mixed-citation></ref><ref id="bibr36-0269216318763225"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opasich</surname><given-names>C</given-names></name><name><surname>Gualco</surname><given-names>A</given-names></name><name><surname>De</surname><given-names>FS</given-names></name><etal>et al</etal></person-group>
<article-title>Physical and emotional symptom burden of patients with end-stage heart failure: what to measure, how and why</article-title>. <source>J Cardiovasc Med</source>
<year>2008</year>; <volume>9</volume>(<issue>11</issue>): <fpage>1104</fpage>&#x02013;<lpage>1108</lpage>.</mixed-citation></ref><ref id="bibr37-0269216318763225"><label>37</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kind</surname><given-names>P.</given-names></name></person-group>
<article-title>The EuroQoL instrument: an index of health-related quality of life</article-title>. In: <person-group person-group-type="editor"><name><surname>Spilker</surname><given-names>B</given-names></name></person-group> (ed.) <source>Quality of life and pharmacoeconomics in clinical trials</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott-Raven</publisher-name>, <year>1996</year>.</mixed-citation></ref><ref id="bibr38-0269216318763225"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP.</given-names></name></person-group>
<article-title>The hospital anxiety and depression scale</article-title>. <source>Acta Psychiatr Scand</source>
<year>1983</year>; <volume>67</volume>(<issue>6</issue>): <fpage>361</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation></ref><ref id="bibr39-0269216318763225"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higginson</surname><given-names>IJ</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Short-form Zarit caregiver burden interviews were valid in advanced conditions</article-title>. <source>J Clin Epidemiol</source>
<year>2010</year>; <volume>63</volume>(<issue>5</issue>): <fpage>535</fpage>&#x02013;<lpage>542</lpage>.<pub-id pub-id-type="pmid">19836205</pub-id></mixed-citation></ref><ref id="bibr40-0269216318763225"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spertus</surname><given-names>J</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Conard</surname><given-names>MW</given-names></name><etal>et al</etal></person-group>
<article-title>Monitoring clinical changes in patients with heart failure: a comparison of methods</article-title>. <source>Am Heart J</source>
<year>2005</year>; <volume>150</volume>(<issue>4</issue>): <fpage>707</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">16209970</pub-id></mixed-citation></ref><ref id="bibr41-0269216318763225"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MJ</given-names></name><name><surname>Bland</surname><given-names>JM</given-names></name><name><surname>Oxberry</surname><given-names>SG</given-names></name><etal>et al</etal></person-group>
<article-title>Clinically important differences in the intensity of chronic refractory breathlessness</article-title>. <source>J Pain Symptom Manage</source>
<year>2013</year>; <volume>46</volume>(<issue>6</issue>): <fpage>957</fpage>&#x02013;<lpage>963</lpage>.<pub-id pub-id-type="pmid">23608121</pub-id></mixed-citation></ref><ref id="bibr42-0269216318763225"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hussain</surname><given-names>JA</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Langan</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Missing data in randomized controlled trials testing palliative interventions pose a significant risk of bias and loss of power: a systematic review and meta-analyses</article-title>. <source>J Clin Epidemiol</source>
<year>2016</year>; <volume>74</volume>: <fpage>57</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">26718729</pub-id></mixed-citation></ref><ref id="bibr43-0269216318763225"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kane</surname><given-names>PM</given-names></name><name><surname>Murtagh</surname><given-names>FE</given-names></name><name><surname>Ryan</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>The gap between policy and practice: a systematic review of patient-centred care interventions in chronic heart failure</article-title>. <source>Heart Fail Rev</source>
<year>2015</year>; <volume>20</volume>(<issue>6</issue>): <fpage>673</fpage>&#x02013;<lpage>687</lpage>.<pub-id pub-id-type="pmid">26435042</pub-id></mixed-citation></ref></ref-list></back></article>